The Indian government is proposing new regulations that would bar the prescription of cough syrups for children under two years of age and discourage their use for those under five. This initiative, part of the draft National Formulary of India (NFI) 2026 released by the Indian Pharmacopoeia Commission (IPC), comes in response to safety concerns following contamination-related deaths linked to toxic industrial solvents such as diethylene glycol (DEG) and ethylene glycol (EG). These contaminants have been associated with over 140 global deaths, including 24 in India in late 2025. The draft NFI aims to standardize drug information, providing guidance on dosage and safety, and explicitly states that cough medications should not be prescribed to very young children without careful evaluation. Pharmaceutical manufacturers will now be required to use pharmacopoeial-grade solvents and conduct rigorous testing of their products. Public health experts have welcomed these changes, advocating for non-drug treatments for coughs in young children, emphasizing the need to address underlying causes rather than merely suppressing symptoms. This proposal follows a series of product recalls and advisories aimed at strengthening drug safety standards in India.